A 75% plus increase in good days/month with eptinezumab is associated with improved migraine symptoms, brain fog, and overall ...

MR is associated with better treatment response than gepants in patients with migraine who previously had an inadequate ...

Patients with migraine with aura show reduced migraine symptoms, less rescue medication use, and more sustained pain relief ...

Most pediatric patients with migraine have normal imaging, supporting that routine scans rarely aid diagnosis or alter ...

CoQ10 supplementation is associated with headache resolution among pediatric patients with new daily persistent headache.

Among children and adolescents with episodic migraine, fremanezumab significantly reduced monthly migraine days.

Psilocybin therapy improved cognitive performance, reduced mood dysfunction, motor, and nonmotor symptoms in patients with Parkinson disease.

Dr L’Erario discusses neurologic care for TGD patients, highlighting key challenges, best practices, & steps toward more inclusive treatment.

Fremanezumab vs placebo significantly reduced monthly migraine days and depressive symptoms in patients with migraine and comorbid major depressive disorder.

The Huntington disease Digital Motor Score, derived from smartphone sensor-based motor tests, can improve detection of disease progression.

Mindfulness and transcranial direct current stimulation offer therapeutic benefit for reducing situational urgency urinary incontinence symptoms in women.

For cancer patients with a major depressive disorder, a single dose of psilocybin combined with psychological support can provide sustained relief.